Abecma

FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
Reuters
Fri, 04/5/24 - 11:40 am
Bristol Myers Squibb
2seventybio
Abecma
cell therapy
Despite early death concerns, FDA advisers back J&J and Legend's Carvykti and BMS' Abecma for earlier myeloma
Fierce Pharma
Sun, 03/17/24 - 09:30 pm
JNJ
Legend Biotech
CAR-T
FDA
Carvykti
Abecma
FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma
BioSpace
Mon, 03/11/24 - 11:53 am
CAR-T
Multiple Myeloma
FDA
Bristol Myers Squibb
2seventy bio
Abecma
JNJ
Legend Biotech
Carvykti
FDA sets date for high-profile CAR-T adcomm for Bristol's Abecma, J&J's Carvykti
Fierce Pharma
Sun, 02/4/24 - 12:39 pm
Bristol Myers Squibb
Abecma
FRDA
CAR-T
JNJ
Carvykti
2seventy bio to sell experimental cell therapies, names new CEO
Reuters
Tue, 01/30/24 - 10:23 am
2seventy bio
Regeneron
Abecma
cell therapy
ASH: Abecma’s survival data show why FDA wanted expert meeting on the Bristol Myers cell therapy
Fierce Pharma
Mon, 12/11/23 - 10:55 pm
ASH 2023
Abecma
FDA
CAR-T
Bristol Myers Squibb
FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
Reuters
Mon, 11/20/23 - 10:12 am
Bristol Myers Squibb
2seventy bio
blood cancer
FDA
Abecma
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
Fierce Pharma
Wed, 04/19/23 - 11:24 am
CAR-T
Bristol Myers Squibb
JNJ
Legend Biotech
AACR
Multiple Myeloma
Carvykti
Abecma
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Fierce Pharma
Sun, 02/12/23 - 07:46 pm
Bristol Myers Squibb
Abecma
CAR-T
Multiple Myeloma
ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?
Fierce Pharma
Mon, 12/12/22 - 10:59 pm
Bristol Myers Squibb
ASH 2022
Abecma
clinical trials
Multiple Myeloma
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Fierce Pharma
Thu, 10/27/22 - 11:04 am
Bristol Myers Squibb
generics
Revlimid
Abecma
Breyanzi
Pharma CEOs
Giovanni Caforio
Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma
BioPharma Dive
Wed, 08/10/22 - 11:34 pm
Bristol Myers Squibb
2seventy bio
Abecma
CAR-T
Multiple Myeloma
Bristol's Abecma, Amgen's Lumakras headline record-setting oncology launch class as costs continue to balloon: IQVIA
Fierce Pharma
Thu, 05/26/22 - 10:53 pm
oncology
cancer
IQVIA
Bristol Myers Squibb
Abecma
Amgen
Lumakras
Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms
Fierce Pharma
Fri, 02/4/22 - 11:22 am
Bristol Myers Squibb
CAR-T
Breyanzi
Abecma
As Abecma sales take off, Bristol Myers and 2seventy scrap a follow-up CAR-T
Endpoints
Thu, 01/13/22 - 07:21 am
Bristol Myers Squibb
2seventy bio
Abecma
bb21217
CAR-T
Bristol Myers sees automation, virtual reality on the horizon for pair of new CAR-T manufacturing plants
Fierce Pharma
Mon, 05/3/21 - 11:11 am
Bristol Myers Squibb
CAR-T
drug manufacturing
Breyanzi
Abecma
Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts
Fierce Pharma
Mon, 03/29/21 - 10:55 pm
Bristol Myers Squibb
Bluebird Bio
CAR-T
JNJ
Legend Biotech
Abecma
FDA approves first CAR-T cell therapy for multiple myeloma
BioPharma Dive
Mon, 03/29/21 - 10:56 pm
Bristol-Myers Squibb
Bluebird Bio
CAR-T
Multiple Myeloma
Abecma
FDA